

Angela D Angelo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8621517/angela-dangelo-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124 papers	2,961 citations	29 h-index	49 g-index
130 ext. papers	3,358 ext. citations	4.4 avg, IF	5.07 L-index

#	Paper	IF	Citations
124	Evaluation of the Effect on Sexual Performance of a Nutraceutical Combination Containing Alpha Lipoic Acid, L. and , Compared to Placebo, Avanafil or a Combination of Nutraceutical Plus Avanafil in Males With Type 2 Diabetes Mellitus With Erectile Dysfunction.. <i>Frontiers in Endocrinology</i> , 2022 , 13, 847240	5.7	0
123	Psoriasis and Diabetes, a Dangerous Association: Evaluation of Insulin Resistance, Lipid Abnormalities, and Cardiovascular Risk Biomarkers. <i>Frontiers in Medicine</i> , 2021 , 8, 605691	4.9	5
122	Nutraceutical Approach to Preventing Coronavirus Disease 2019 and Related Complications. <i>Frontiers in Immunology</i> , 2021 , 12, 582556	8.4	2
121	Metabolic Actions of a Supplement of Ilex Paraguariensis (An Extract of the Leaf Standardized to 2% I-Deoxinojirimicina), White Mulberry and Chromium Picolinate in Nondiabetic Subjects with Dysglycemia: A Randomized Trial. <i>Life</i> , 2021 , 11,	3	1
120	Effects of experimental colitis in rats on incretin levels, inflammatory markers, and enteric neuronal function. <i>Archives of Medical Science</i> , 2021 , 17, 1087-1092	2.9	0
119	A role for quercetin in coronavirus disease 2019 (COVID-19). <i>Phytotherapy Research</i> , 2021 , 35, 1230-1236	6.7	78
118	Effects of Oral Administration of Alprazolam and Lorazepam as Hypnotics on Cardiovascular Parameters in Hypertensive Patients. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 191-195	1.7	0
117	Safety and Efficacy of Alpha Lipoic Acid During 4 Years of Observation: A Retrospective, Clinical Trial in Healthy Subjects in Primary Prevention. <i>Drug Design, Development and Therapy</i> , 2020 , 14, 5367-5374	4.4	4
116	An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2020 , 13, 653-661	3.4	9
115	Lipid-lowering nutraceuticals update on scientific evidence. <i>Journal of Cardiovascular Medicine</i> , 2020 , 21, 845-859	1.9	7
114	Vitamin D3 supplementation improves glycemic control in type 2 diabetic patients: Results from an Italian clinical trial. <i>International Journal for Vitamin and Nutrition Research</i> , 2020 , 1-10	1.7	2
113	Change of some oxidative stress parameters after supplementation with whey protein isolate in patients with type 2 diabetes. <i>Nutrition</i> , 2020 , 73, 110700	4.8	12
112	Adipose tissue dysfunction and metabolic disorders: Is it possible to predict who will develop type 2 diabetes mellitus? Role of markers in the progression of diabetes in obese patients (The RESISTIN trial). <i>Cytokine</i> , 2020 , 127, 154947	4	22
111	Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3219	7.5	3
110	Ilex paraguariensis, white mulberry and chromium picolinate in patients with pre-diabetes. <i>Phytotherapy Research</i> , 2020 , 34, 1377-1384	6.7	2
109	Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy. <i>Journal of Clinical Pharmacology</i> , 2019 , 59, 1391-1399	2.9	5
108	Ascophyllum nodosum and Fucus vesiculosus on glycemic status and on endothelial damage markers in dysglycemic patients. <i>Phytotherapy Research</i> , 2019 , 33, 791-797	6.7	9

107	Diazepam as an oral hypnotic increases nocturnal blood pressure in the elderly. <i>Aging Clinical and Experimental Research</i> , 2019 , 31, 463-468	4.8	4
106	Coenzyme q10 liquid supplementation in dyslipidemic subjects with statin-related clinical symptoms: a double-blind, randomized, placebo-controlled study. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 3647-3655	4.4	9
105	Ascophyllum Nodosum, Fucus Vesiculosus and chromium picolinate nutraceutical composition can help to treat type 2 diabetic patients. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2019 , 12, 1861-1865	3.4	5
104	Effects of a nutraceutical combination of monacolin, Ebryanol and ̢-aminobutyric acid on lipid profile and C-reactive protein in mice. <i>Archives of Medical Science</i> , 2019 , 15, 792-796	2.9	1
103	A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effectiveness of a Food Supplement Containing Creatine and D-Ribose Combined with a Physical Exercise Program in Increasing Stress Tolerance in Patients with Ischemic Heart Disease. <i>Nutrients</i> , 2019 , 11,	6.7	2
102	Effects on oral fat load of a nutraceutical combination of fermented red rice, sterol esters and stanols, curcumin, and olive polyphenols: A randomized, placebo controlled trial. <i>Phytomedicine</i> , 2018 , 42, 75-82	6.5	12
101	Evaluation of BAG3 levels in healthy subjects, hypertensive patients, and hypertensive diabetic patients. <i>Journal of Cellular Physiology</i> , 2018 , 233, 1791-1795	7	3
100	Response to an oral fat load and effects on lipid profile, glycemia and high-sensitivity C-reactive protein after soybean extract consumption. <i>Archives of Medical Science</i> , 2018 , 14, 760-765	2.9	1
99	Retraction notice to "Results from a 12 months, randomized, clinical trial comparing an olmesartan/amlodipine single pill combination to olmesartan and amlodipine monotherapies on blood pressure and inflammatin" [European Journal of Pharmaceutical Sciences 51C (2013) 26-33]. <i>European Journal of Pharmaceutical Sciences</i> , 2018 , 123, 584	5.1	
98	A randomized, double-blind clinical trial of canrenone vs hydrochlorothiazide in addition to angiotensin II receptor blockers in hypertensive type 2 diabetic patients. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 2611-2616	4.4	4
97	Effects of two different dialytic treatments on inflammatory markers in people with end-stage renal disease with and without type 2 diabetes mellitus. <i>Cytokine</i> , 2017 , 92, 75-79	4	6
96	Retraction notice to "Acarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled study". <i>Journal of Diabetes and Its Complications</i> , 2017 , 31, 1248	3.2	
95	Effect of ramipril/hydrochlorothiazide and ramipril/canrenone combination on atrial fibrillation recurrence in hypertensive type 2 diabetic patients with and without cardiac autonomic neuropathy. <i>Archives of Medical Science</i> , 2017 , 13, 550-557	2.9	3
94	Ambulatory 24-h ECG monitoring and cardiovascular autonomic assessment for the screening of silent myocardial ischemia in elderly type 2 diabetic hypertensive patients. <i>Heart and Vessels</i> , 2017 , 32, 507-513	2.1	3
93	Effects of a Combination of Berberis aristata, Silybum marianum and Monacolin on Lipid Profile in Subjects at Low Cardiovascular Risk; A Double-Blind, Randomized, Placebo-Controlled Trial. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	12
92	Evaluation of the Effects of Mesoglycan on Some Markers of Endothelial Damage and Walking Distance in Diabetic Patients with Peripheral Arterial Disease. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	4
91	The role of a fixed Berberis aristata/Silybum marianum combination in the treatment of type 1 diabetes mellitus. <i>Clinical Nutrition</i> , 2016 , 35, 1091-5	5.9	19
90	Barnidipine compared to lercanidipine in addition to losartan on endothelial damage and oxidative stress parameters in patients with hypertension and type 2 diabetes mellitus. <i>BMC Cardiovascular Disorders</i> , 2016 , 16, 66	2.3	13

89	A Clinical Trial about a Food Supplement Containing Lipoic Acid on Oxidative Stress Markers in Type 2 Diabetic Patients. <i>International Journal of Molecular Sciences</i> , 2016 , 17,	6.3	39
88	Effects of n-3 pufas on fasting plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose tolerance. <i>BioFactors</i> , 2016 , 42, 316-22	6.1	32
87	Sitagliptin in type 2 diabetes mellitus: Efficacy after five years of therapy. <i>Pharmacological Research</i> , 2015 , 100, 127-34	10.2	13
86	Perindopril and barnidipine alone or combined with simvastatin on hepatic steatosis and inflammatory parameters in hypertensive patients. <i>European Journal of Pharmacology</i> , 2015 , 766, 31-6	5.3	9
85	Retraction notice to "Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies": J Am Soc Hypertens 7 (2013) 32-39. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 821		
84	Retraction notice to "Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study": J Am Soc Hypertens 8 (2014) 422-428. <i>Journal of the American Society of Hypertension</i> , 2015 , 9, 822		
83	Comparison of the effects of barnidipine+losartan compared with telmisartan+hydrochlorothiazide on several parameters of insulin sensitivity in patients with hypertension and type 2 diabetes mellitus. <i>Hypertension Research</i> , 2015 , 38, 690-4	4.7	12
82	Barnidipine or Lercanidipine on Echocardiographic Parameters in Hypertensive, Type 2 Diabetics with Left Ventricular Hypertrophy: A Randomized Clinical Trial. <i>Scientific Reports</i> , 2015 , 5, 12603	4.9	3
81	Bicarbonate dialysis compared to hemodiafiltration on glycemic excursions in patients with end-stage renal disease with and without type 2 diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 1136-41	3.2	1
80	A study about the relevance of adding acetylsalicylic acid in primary prevention in subjects with type 2 diabetes mellitus: effects on some new emerging biomarkers of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2015 , 14, 95	8.7	7
79	Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial. <i>Pharmacotherapy</i> , 2015 , 35, 983-90	5.8	5
78	Berberis aristata combined with Silybum marianum on lipid profile in patients not tolerating statins at high doses. <i>Atherosclerosis</i> , 2015 , 239, 87-92	3.1	24
77	Prevalence and associations of erectile dysfunction in a sample of Italian males with type 2 diabetes. <i>Diabetes Research and Clinical Practice</i> , 2015 , 108, 329-35	7.4	23
76	Berberis aristata/Silybum marianum fixed combination (Berberol(®)) effects on lipid profile in dyslipidemic patients intolerant to statins at high dosages: a randomized, placebo-controlled, clinical trial. <i>Phytomedicine</i> , 2015 , 22, 231-7	6.5	18
75	The effects of canrenone on inflammatory markers in patients with metabolic syndrome. <i>Annals of Medicine</i> , 2015 , 47, 47-52	1.5	7
74	Different aspects of sartan + calcium antagonist association compared to the single therapy on inflammation and metabolic parameters in hypertensive patients. <i>Inflammation</i> , 2014 , 37, 154-62	5.1	5
73	Enalapril/lercanidipine combination on markers of cardiovascular risk: a randomized study. <i>Journal of the American Society of Hypertension</i> , 2014 , 8, 422-8		5
72	Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2014 , 63, 957-67	12.7	23

71	Adipocytokine levels in obese and non-obese subjects: an observational study. <i>Inflammation</i> , 2013 , 36, 914-20	5.1	71
70	Berberis aristata/Silybum marianum fixed combination on lipid profile and insulin secretion in dyslipidemic patients. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 1495-506	5.4	37
69	Olmesartan/amlodipine combination versus olmesartan or amlodipine monotherapies on blood pressure and insulin resistance in a sample of hypertensive patients. <i>Clinical and Experimental Hypertension</i> , 2013 , 35, 301-7	2.2	5
68	Variation of some inflammatory markers in hypertensive patients after 1 year of olmesartan/amlodipine single-pill combination compared with olmesartan or amlodipine monotherapies. <i>Journal of the American Society of Hypertension</i> , 2013 , 7, 32-9		7
67	A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. <i>Diabetes Technology and Therapeutics</i> , 2013 , 15, 214-22	8.1	14
66	Effects of berberine on lipid profile in subjects with low cardiovascular risk. <i>Expert Opinion on Biological Therapy</i> , 2013 , 13, 475-82	5.4	64
65	Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis: possible correlation with clinical presentation. <i>Disease Markers</i> , 2013 , 35, 135-40	3.2	21
64	Ultrasonography modifications of visceral and subcutaneous adipose tissue after pioglitazone or glibenclamide therapy combined with rosuvastatin in type 2 diabetic patients not well controlled by metformin. <i>European Journal of Gastroenterology and Hepatology</i> , 2013 , 25, 1113-22	2.2	12
63	Evaluation of safety and efficacy of a fixed olmesartan/amlodipine combination therapy compared to single monotherapies. <i>Expert Opinion on Drug Safety</i> , 2013 , 12, 621-9	4.1	4
62	Variations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metformin. <i>Internal Medicine</i> , 2013 , 52, 2179-87	1.1	23
61	Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. <i>Scientific World Journal, The</i> , 2013 , 2013, 584504	2.2	25
60	Glyco-metabolic profile among type 2 diabetic patients with erectile dysfunction. <i>Endocrine Journal</i> , 2012 , 59, 611-9	2.9	9
59	A randomized, double-blind, placebo-controlled trial evaluating sitagliptin action on insulin resistance parameters and β cell function. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2433-42	4	18
58	Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. <i>Journal of Clinical Lipidology</i> , 2012 , 6, 553-64	4.9	43
57	Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. <i>Mediators of Inflammation</i> , 2012 , 2012, 874149	4.3	9
56	Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2581-91	4	21
55	Long-term effects of a multidisciplinary treatment of uncomplicated obesity on carotid intima-media thickness. <i>Obesity</i> , 2011 , 19, 1187-92	8	19
54	Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients. <i>Fundamental and Clinical Pharmacology</i> , 2011 , 25, 642-51	3.1	22

53	Molecular biology-based assessment of vitamin E-coated dialyzer effects on oxidative stress, inflammation, and vascular remodeling. <i>Artificial Organs</i> , 2011 , 35, E33-9	2.6	17
52	Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. <i>Metabolism: Clinical and Experimental</i> , 2011 , 60, 421-9	12.7	28
51	Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load. <i>European Journal of Pharmacology</i> , 2011 , 651, 240-50	5.3	41
50	Effects of n-3 PUFA on insulin resistance after an oral fat load. <i>European Journal of Lipid Science and Technology</i> , 2011 , 113, 950-960	3	16
49	Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. <i>Hypertension Research</i> , 2011 , 34, 145-51	4.7	31
48	Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2010 , 13, 378-90	3.4	10
47	Candesartan effect on inflammation in hypertension. <i>Hypertension Research</i> , 2010 , 33, 209-13	4.7	18
46	Comparison of orlistat treatment and placebo in obese type 2 diabetic patients. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 1971-82	4	25
45	Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. <i>Hypertension Research</i> , 2010 , 33, 790-5	4.7	21
44	Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. <i>Microvascular Research</i> , 2010 , 79, 144-9	3.7	22
43	Effects of a standardized oral fat load on vascular remodelling markers in healthy subjects. <i>Microvascular Research</i> , 2010 , 80, 110-5	3.7	24
42	Angiotensin II signaling via type 2 receptors in a human model of vascular hyporeactivity: implications for hypertension. <i>Journal of Hypertension</i> , 2010 , 28, 111-8	1.9	39
41	Orlistat and L-carnitine compared to orlistat alone on insulin resistance in obese diabetic patients. <i>Endocrine Journal</i> , 2010 , 57, 777-86	2.9	42
40	Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. <i>Internal Medicine</i> , 2010 , 49, 1717-25	1.1	29
39	Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. <i>Metabolism: Clinical and Experimental</i> , 2010 , 59, 887-95	12.7	93
38	Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. <i>Current Medical Research and Opinion</i> , 2009 , 25, 1973-83	2.5	33
37	Continuous glucose monitoring system in free-living healthy subjects: results from a pilot study. <i>Diabetes Technology and Therapeutics</i> , 2009 , 11, 159-69	8.1	16
36	Oral fat load effects on inflammation and endothelial stress markers in healthy subjects. <i>Heart and Vessels</i> , 2009 , 24, 204-10	2.1	37

35	Modulation of adipokines and vascular remodelling markers during OGTT with acarbose or pioglitazone treatment. <i>Biomedicine and Pharmacotherapy</i> , 2009 , 63, 723-33	7.5	14
34	Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60Q study. <i>Metabolism: Clinical and Experimental</i> , 2009 , 58, 1059-66	12.7	18
33	Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. <i>Current Medical Research and Opinion</i> , 2009 , 25, 607-15	2.5	30
32	Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensives. <i>Blood Pressure</i> , 2009 , 18, 111-6	1.7	8
31	Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. <i>Internal Medicine</i> , 2009 , 48, 265-71	1.1	10
30	Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI). <i>Endocrine Journal</i> , 2009 , 56, 571-8	2.9	5
29	Evaluation of metalloproteinase 2 and 9 levels and their inhibitors in combined dyslipidemia. <i>Clinical and Investigative Medicine</i> , 2009 , 32, E124-32	0.9	32
28	Rosiglitazone therapy improves insulin resistance parameters in overweight and obese diabetic patients intolerant to metformin. <i>Archives of Medical Research</i> , 2008 , 39, 412-9	6.6	15
27	Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone. <i>Metabolism: Clinical and Experimental</i> , 2008 , 57, 1552-7	12.7	14
26	Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 45-51		29
25	Comparison between metalloproteinases-2 and -9 in healthy subjects, diabetics, and subjects with acute coronary syndrome. <i>Heart and Vessels</i> , 2007 , 22, 361-70	2.1	55
24	Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. <i>Hypertension Research</i> , 2007 , 30, 387-94	4.7	52
23	Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2007 , 14, 175-83		11
22	Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. <i>Internal Medicine</i> , 2007 , 46, 1837-46	4.1	20
21	Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. <i>Clinical Therapeutics</i> , 2007 , 29, 602-10	3.5	20
20	Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. <i>Endothelium: Journal of Endothelial Cell Research</i> , 2006 , 13, 227-31		107
19	Association of plasma eotaxin levels with the presence and extent of angiographic coronary artery disease. <i>Atherosclerosis</i> , 2006 , 186, 140-5	3.1	54
18	Elevated plasma levels of lipoprotein(a) in psychiatric patients: a possible contribution to increased vascular risk. <i>European Psychiatry</i> , 2006 , 21, 129-33	6	11

17	Synergistic effect of doxazosin and acarbose in improving metabolic control in patients with impaired glucose tolerance. <i>Clinical Drug Investigation</i> , 2006 , 26, 529-39	3.2	9
16	Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. <i>Clinical Therapeutics</i> , 2006 , 28, 679-88	3.5	55
15	Effect of doxazosin on C-reactive protein plasma levels and on nitric oxide in patients with hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47, 508-12	3.1	7
14	High levels of soluble receptor for advanced glycation end products may be a marker of extreme longevity in humans. <i>Journal of the American Geriatrics Society</i> , 2006 , 54, 1149-50	5.6	55
13	Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-alpha. <i>Hypertension Research</i> , 2006 , 29, 849-56	4.7	70
12	The apolipoprotein(a) component of lipoprotein(a) mediates binding to laminin: contribution to selective retention of lipoprotein(a) in atherosclerotic lesions. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2005 , 1687, 1-10	5	5
11	Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. <i>Journal of Hypertension</i> , 2005 , 23, 1725-9	1.9	142
10	Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride. <i>Hypertension Research</i> , 2005 , 28, 917-24	4.7	42
9	Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 1032-7	9.4	320
8	Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. <i>Archives of Neurology</i> , 2005 , 62, 1734-6		163
7	Lipoprotein(a)-associated atherothrombotic risk in hemodialysis patients. <i>American Journal of Nephrology</i> , 2004 , 24, 221-9	4.6	11
6	Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: relation with clinical presentation. <i>Clinica Chimica Acta</i> , 2004 , 350, 159-65	6.2	11
5	Apolipoprotein(a) null phenotype is related to a delayed age at onset of Alzheimer's disease. <i>Neuroscience Letters</i> , 2004 , 357, 45-8	3.3	11
4	Apolipoprotein(a) phenotypes are reliable biomarkers for familial aggregation of coronary heart disease. <i>International Journal of Molecular Medicine</i> , 2004 , 13, 243-7	4.4	12
3	Relationship between apolipoprotein(a) size polymorphism and coronary heart disease in overweight subjects. <i>BMC Cardiovascular Disorders</i> , 2003 , 3, 12	2.3	5
2	Increased urinary NO ₂ -/NO ₃ - and cyclic guanosine monophosphate levels in patients with Bartter's syndrome: relationship to vascular reactivity. <i>American Journal of Kidney Diseases</i> , 1996 , 27, 784-9	7.4	48
1	Metformin: From Immediate Release to Extended Release Formula, Effectiveness, And Safety in Patients With Chronic Kidney Disease. <i>European Medical Journal Diabetes</i> , 70-78	1	